C4 Therapeutics, Inc. (NASDAQ:CCCC) Forecasted to Post FY2023 Earnings of ($2.84) Per Share
C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) – Stock analysts at HC Wainwright cut their FY2023 EPS estimates for C4 Therapeutics in a report released on Monday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($2.84) for the year, down from their previous estimate of […]